SAB Biotherapeutics (NASDAQ:SABS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of SAB Biotherapeutics (NASDAQ:SABS) from a strong sell rating to a sell rating in a research report sent to investors on Monday morning.

Several other equities analysts also recently weighed in on SABS. Weiss Ratings downgraded SAB Biotherapeutics from a “sell (d+)” rating to a “sell (e+)” rating in a research report on Thursday, August 6th. Citigroup assumed coverage on SAB Biotherapeutics in a research report on Friday, May 22nd. They set a “buy” rating and a $11.00 price target for the company. Leerink Partners increased their price objective on SAB Biotherapeutics from $7.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, June 15th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of SAB Biotherapeutics in a report on Monday, June 15th. Finally, Chardan Capital lifted their target price on shares of SAB Biotherapeutics from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Wednesday, June 17th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $12.00.

SAB Biotherapeutics Stock Up 1.1%

SABS stock opened at $3.80 on Monday. SAB Biotherapeutics has a 52 week low of $1.85 and a 52 week high of $5.15. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.01. The firm has a 50-day simple moving average of $3.70 and a 200-day simple moving average of $3.82. The stock has a market capitalization of $345.76 million, a P/E ratio of -2.92 and a beta of 0.53.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.28) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.28). Equities analysts forecast that SAB Biotherapeutics will post -1.17 earnings per share for the current fiscal year.

Institutional Investors Weigh In On SAB Biotherapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp purchased a new position in SAB Biotherapeutics during the second quarter worth about $421,000. Seven Fleet Capital Management LP acquired a new stake in shares of SAB Biotherapeutics during the 1st quarter worth approximately $1,915,000. DV Trading LLC acquired a new stake in shares of SAB Biotherapeutics during the 1st quarter worth approximately $1,532,000. Perceptive Advisors LLC raised its position in shares of SAB Biotherapeutics by 700.8% during the 1st quarter. Perceptive Advisors LLC now owns 6,431,743 shares of the company’s stock valued at $24,634,000 after buying an additional 5,628,533 shares during the period. Finally, Bank of America Corp DE raised its position in shares of SAB Biotherapeutics by 424.8% during the 1st quarter. Bank of America Corp DE now owns 55,697 shares of the company’s stock valued at $213,000 after buying an additional 45,084 shares during the period. 7.82% of the stock is currently owned by institutional investors and hedge funds.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.